|Back to main|
Patent Challenge from Perrigo - Analyst Blog
5/31/2013 6:28:00 PM
) recently announced that it is seeking US approval to market its
generic version of
Eli Lilly and Company
) Axiron. The drug is marketed for treating males aged above 18
years, who have low or no testosterone. To achieve the objective,
Perrigo filed an Abbreviated New Drug Application (ANDA) with the
FDA. Perrigo's application has been challenged.
Sales of new products boosted segmental revenues by $18
million. Inclusion of results of Rosemont Pharma boosted sales by
$8 million. Adjusted gross profit for the segment increased 19.3%
to $109.7 million.
ALLERGAN INC (AGN): Free Stock Analysis Report
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
PERRIGO COMPANY (PRGO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research